Physician profile
Robert Lee Larson
NPI 1881617488
$6,970.96
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $1,652 · 2021: $2,125 · 2022: $1,305.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $927.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $814.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $624.45 | 2019-2022 | |
| Pfizer INC. | $579.18 | 2019-2022 | |
| Abbvie INC. | $429.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $373.21 | 2019-2022 | |
| Lilly USA, LLC | $369.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $341.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $269.39 | 2019-2022 | |
| Novo Nordisk INC | $242.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $222.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $215.63 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $157.60 | 2021 | |
| Eisai INC. | $140.55 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $139.02 | 2021-2022 |
Show all 41 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.